Download our whitepaper,
Navigating the Landscape of COPD
Clinical Trials: From Diagnosis
Criteria to Pivotal Endpoints
What's Inside:
- Key FDA-Approved Pivotal Endpoints for COPD Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for COPD.
- Comprehensive Analysis of FDA-Approved COPD Drugs.
- How Diagnostic Criteria for COPD Have Evolved and Impact Research.
- Overcoming Common Pitfalls in COPD Clinical Trials.
- And additional insights to drive your trial’s success.
Access your complimentary whitepaper today:
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder characterized by chronic cough, sputum production, and dyspnea (shortness of breath). It often includes episodes of exacerbation, where symptoms worsen significantly.
COPD primarily affects older adults and is most commonly linked to smoking, though environmental factors such as air pollution and genetic predispositions also play a role. The disease significantly impacts quality of life and requires long-term management.
Recent advances in research have shifted the understanding of COPD from being purely a respiratory condition to a multifactorial disease involving inflammation, oxidative stress, and genetic components. This broader perspective has led to more effective therapies focused on improving lung function, managing symptoms, and enhancing overall patient well-being.
At iNGENū, our team of researchers and clinicians specializes in designing and conducting innovative clinical studies. By utilizing adaptive trial designs and patient-centric strategies, we accelerate the development of new therapies aimed at improving outcomes for individuals living with COPD.
384 million
people worldwide are estimated to have COPD
Exposure to high levels of air pollution increases the risk of COPD by
25%
85–90%
of COPD cases are caused by smoking
Our clinical team has over
120 years
of combined clinical trial experience